News und Analysen
Lysogene Reports its Cash Position as of 31 December 2019
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today
Navidea Biopharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Canopy Growth: Was Aurora kann...
...kann Canopy Growth (WKN: A140QA) schon lange. Nein, Canopy kann es sogar viel besser. Der Cannabis-Marktführer meldet heute Quartalszahlen, die im Gegensatz zu den Horrorzahlen von Aurora
IMV Announces Board Retirement
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced that Albert Scardino will retire from the IMV Board of
Navidea Biopharmaceuticals Announces $4.2 Million Sale of Ohio Court Judgment and $3.4 Million Equity Raise Representing $7.6 Million in Additional Funding
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Dexcom Reports Fourth Quarter and Fiscal Year 2019 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2019.
Fourth Quarter 2019 Highlights:
-
Revenue grew 37% versus the
Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter and full year 2019 financial results on Monday, February 24, 2020, after the close of the U.S. financial markets. Clovis’
Sensorion Announces the Full Conversion of Sofinnova Partners Convertible Bonds Into Ordinary Shares
Regulatory News:
Sensorion (FR0012596468 – ALSEN / PEA-PME eligible) (Paris:ALSEN), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore
Quidel Reports Fourth Quarter and Full Year 2019 Financial Results
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the
Illumina to Webcast Upcoming Investor Conference Presentations
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conferences and invited investors to participate via webcast.
SVB Leerink Global
Sangamo Therapeutics Appoints John Markels to Its Board of Directors
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. John Markels, an accomplished pharmaceutical executive with three decades of general
4SC: Das könnte für Furore sorgen
4SC (WKN: A14KL7) präsentiert auf dem vom 12.-14. Februar in Barcelona stattfindenden "World Congress of Cutaneous Lymphomas" ein Update zum Fortschritt seiner „Resmain-Studie“ sowie präklinische
Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 9th Annual SVB Leerink Global Healthcare Conference on
Palatin: Aktie fällt – wer greift nach dem Sex-Pen?
Im vergangenen Jahr feierten SD-Leser bis zu +600% Kursgewinn mit der Aktie von Palatin Technologies (WKN: A1C538). Wir rieten rechtzeitig zum Ausstieg, bevor der Kurs wieder stark nachgab. Doch
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2019 Results and Provides 2020 Guidance
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2019 and provided guidance for 2020. For the quarter, revenue was $691.1
MEDICREA® Announces FDA Clearance of the World’s First Patient-Matched Spinal Interbody Cages
MEDICREA® (Euronext Growth Paris : FR0004178572 – ALMED, PEA-PME eligible and OTCQX : MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling
Lysogene Announces Presentations at Upcoming 16th WORLDSymposium™ on Lysosomal Diseases
Regulatory News:
Lysogene (Paris:LYS) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today
NANOBIOTIX Announces Fast Track Designation Granted By U.S. FDA For Investigation of First-in-class NBTXR3 In Head and Neck Cancer
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
NanoString to Release Fourth Quarter and Fiscal Year 2019 Financial Results and Host Conference Call on Wednesday, February 26, 2020
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research, today announced that the Company will release fourth quarter and fiscal year 2019
Sensorion Announces the Full Conversion of Invus Convertible Bonds Into Ordinary Shares
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN / PEA-PME eligible), a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 5, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Agilent Technologies Announces Twist Bioscience Agrees to Pay $22.5 Million Settlement in IP Litigation
Agilent Technologies Inc. (NYSE: A) today announced it has reached an agreement with Twist Bioscience under which Twist has agreed to pay Agilent a sum of $22.5 million to settle Agilent’s claims
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that company
Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors
Illumina, Inc. (NASDAQ: ILMN) announced today that Scott Gottlieb, M.D. has joined the company’s Board of Directors, effective February 4, 2020. Dr. Gottlieb is currently a special partner at the
More Than 200 Companies Select Veeva Vault RIM Applications to Streamline Regulatory Operations
Veeva Systems (NYSE:VEEV) today announced an increasing number of life sciences companies are adopting applications in the Veeva Vault RIM Suite to streamline regulatory information management